In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd..
CD19-targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is a CD19-targeting antibody-drug conjugate indicated for R/R DLBCL after at least two systemic treatments. CD19 expression was evaluated in patients receiving Lonca in the LOTIS-2 clinical trial with available tissue samples obtained after last systemic therapy/before Lonca treatment. Lonca cytotoxicity was evaluated in a panel of six lymphoma cell lines with various CD19 expression levels. Quantitative systems pharmacology (QSP) modelling was used to predict Lonca responses. Lonca responses were seen in patients across all CD19 expression levels, including patients with low/no detectable CD19 expression and H-scores at baseline. Similarly, Lonca induced cytotoxicity in cell lines with different levels of CD19 expression, including one with very low expression. QSP modelling predicted that CD19 expression by immunohistochemistry alone does not predict Lonca response, whereas inclusion of CD19 surface density improved response prediction. Virtual patients responded to Lonca with estimated CD19 as low as 1000 molecules/cell of CD19, normally below the immunohistochemistry detection level. We found Lonca is an effective treatment for R/R DLBCL regardless of CD19 expression by immunohistochemistry. These results provide the basis for future studies addressing CD19-targeted agent sequencing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
EJHaem - 5(2024), 1 vom: 21. Feb., Seite 76-83 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caimi, Paolo F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD19 |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/jha2.816 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368964868 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368964868 | ||
| 003 | DE-627 | ||
| 005 | 20240229165030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jha2.816 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368964868 | ||
| 035 | |a (NLM)38406517 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caimi, Paolo F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a CD19-targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is a CD19-targeting antibody-drug conjugate indicated for R/R DLBCL after at least two systemic treatments. CD19 expression was evaluated in patients receiving Lonca in the LOTIS-2 clinical trial with available tissue samples obtained after last systemic therapy/before Lonca treatment. Lonca cytotoxicity was evaluated in a panel of six lymphoma cell lines with various CD19 expression levels. Quantitative systems pharmacology (QSP) modelling was used to predict Lonca responses. Lonca responses were seen in patients across all CD19 expression levels, including patients with low/no detectable CD19 expression and H-scores at baseline. Similarly, Lonca induced cytotoxicity in cell lines with different levels of CD19 expression, including one with very low expression. QSP modelling predicted that CD19 expression by immunohistochemistry alone does not predict Lonca response, whereas inclusion of CD19 surface density improved response prediction. Virtual patients responded to Lonca with estimated CD19 as low as 1000 molecules/cell of CD19, normally below the immunohistochemistry detection level. We found Lonca is an effective treatment for R/R DLBCL regardless of CD19 expression by immunohistochemistry. These results provide the basis for future studies addressing CD19-targeted agent sequencing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD19 | |
| 650 | 4 | |a diffuse large B‐cell lymphoma | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a loncastuximab tesirine | |
| 650 | 4 | |a quantitative systems pharmacology | |
| 700 | 1 | |a Hamadani, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Carlo-Stella, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Nickaeen, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Jordie, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Utsey, Kiersten |e verfasserin |4 aut | |
| 700 | 1 | |a Knab, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Zammarchi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Cucchi, Danilo |e verfasserin |4 aut | |
| 700 | 1 | |a Pantano, Serafino |e verfasserin |4 aut | |
| 700 | 1 | |a Havenith, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Boni, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EJHaem |d 2020 |g 5(2024), 1 vom: 21. Feb., Seite 76-83 |w (DE-627)NLM314118454 |x 2688-6146 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:1 |g day:21 |g month:02 |g pages:76-83 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jha2.816 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 1 |b 21 |c 02 |h 76-83 | ||